John Penn
Vanderbilt Vision Research Center (VVRC)
Vanderbilt Diabetes Research and Training Center (DRTC)
Vanderbilt Eye Institute
Dr. Penn’s research focuses on the molecular and cellular characterization of retinal vascular inflammation and angiogenesis with emphasis on biomarker identification and development of targeted therapies and novel mechanisms of drug delivery to the eye. His work specifically impacts several prevalent causes of irreversible vision loss, including retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. Penn’s lab partners closely with drug companies to develop pre-clinical efficacy data for investigational new drug applications to the FDA.
Dr. Penn’s research focuses on the molecular and cellular characterization of retinal vascular inflammation and angiogenesis with emphasis on biomarker identification and development of targeted therapies and novel mechanisms of drug delivery to the eye. His work specifically impacts several prevalent causes of irreversible vision loss, including retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. Penn’s lab partners closely with drug companies to develop pre-clinical efficacy data for investigational new drug applications to the FDA.
Keywords: vascular inflammation , retina , angiogenesis , vascular biology , eye disease , nanoparticle
Research Area: Drug Design , Diabetes, Obesity, Metabolism , Vascular Biology , Visual Sciences